Comparison of VTD (velcade-thalidomide-dexamethasone) and a conventional chemotherapy induction regimen: effect on stem cell mobilization and engraftment of ASCT (autologous stem cell transplantation) for newly diagnosed multiple myeloma

被引：0
|
作者：
Requena, M. J. [1 ]
Yebra, E. [1 ]
Berberana, M. [1 ]
Payamps, C. [1 ]
Diaz Goizueta, M. [1 ]
Riaza, R. [1 ]
Penalver, M. A. [1 ]
Rodriguez, R. [1 ]
Sanchez Godoy, P. [1 ]
机构：
[1] Hosp Severo Ochoa, Madrid, Spain
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S212 / S213
页数：2
相关论文
共 50 条
  • [1] Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
    Cavo, Michele
    Patriarca, Francesca
    Tacchetti, Paola
    Galli, Monica
    Perrone, Giulia
    Petrucci, Maria Teresa
    Brioli, Annamaria
    Bringhen, Sara
    Pantani, Lucia
    Tosi, Patrizia
    Crippa, Claudia
    Zamagni, Elena
    Di Raimondo, Francesco
    Narni, Franco
    Cellini, Claudia
    Ceecolini, Michela
    Pescosta, Norbert
    Goldaniga, Maria Cecilia
    Montefusco, Vittorio
    Callea, Vincenzo
    De Stefano, Valerio
    Caravita, Tommaso
    Boccadoro, Mario
    Baccarani, Michele
    BLOOD, 2007, 110 (11) : 30A - 30A
  • [2] Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
    Oza, Samir
    Slotky, Ronit
    Vissa, Pranay
    Phull, Pooja
    Kaur, Sukhdeep
    Suh, Hyung C.
    Donato, Michele L.
    Rowley, Scott D.
    Biran, Noa
    Vesole, David H.
    Siegel, David
    Parmar, Harsh
    BLOOD, 2022, 140 : 10441 - 10442
  • [3] Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell transplantation in multiple myeloma
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Oriol, A.
    Terol, M. J.
    Garcia-Larana, J.
    Hernandez, D.
    de la Rubia, J.
    Sureda, A.
    Besalduch, J.
    Palomera, L.
    Gonzalez, Y.
    Echebeste, M. A.
    Diaz-Mediavilla, J.
    de Arriba, F.
    Alegre, A.
    Hernandez, M.
    Lahuerta, J. J.
    Miguel, J. F. San
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S18 - S18
  • [4] Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
    Abdul Hamid Bazarbachi
    Rama Al Hamed
    Florent Malard
    Ali Bazarbachi
    Jean-Luc Harousseau
    Mohamad Mohty
    Blood Cancer Journal, 12
  • [5] Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
    Bazarbachi, Abdul Hamid
    Al Hamed, Rama
    Malard, Florent
    Bazarbachi, Ali
    Harousseau, Jean-Luc
    Mohty, Mohamad
    BLOOD CANCER JOURNAL, 2022, 12 (03)
  • [6] Sequential VAD (vincriestine, adriamycin, dexamethasone) and VTD (velcade, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with velcade for newly diagnosed multiple myeloma: Preliminary analysis of efficacy and safety
    Yoon, S. S.
    Kim, H. J.
    Lee, D. S.
    Lee, S. J.
    Seong, J. M.
    Suh, C.
    Kim, K.
    Eom, H. S.
    Min, Y. H.
    Jung, J. S.
    Kim, C. S.
    Kang, H. J.
    Jang, J. H.
    Lee, J. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 182 - 182
  • [7] Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen
    Jung, Sung-Hoon
    Park, Hyungchul
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Kim, Mi-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (01) : 92 - 97
  • [8] Influence of Stem Cell Mobilization After Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Regimen in Patients with Newly Diagnosed Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD, 2011, 118 (21) : 840 - 840
  • [9] Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen
    Sung-Hoon Jung
    Hyungchul Park
    Jae-Sook Ahn
    Deok-Hwan Yang
    Mi-Young Kim
    Yeo-Kyeoung Kim
    Hyeoung-Joon Kim
    Je-Jung Lee
    International Journal of Hematology, 2013, 97 : 92 - 97
  • [10] EFFICACY OF INDUCTION TREATMENT WITH CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) CHEMOTHERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS ELIGIBLE FOR THE AUTOLOGOUS STEM CELL TRANSPLANTATION
    Bila, J.
    Vujic, D.
    Veljkovic, D.
    Todorovic, M.
    Sefer, D.
    Kraguljac, M.
    Antic, D.
    Andjelic, B.
    Smiljanic, M.
    Jankovic, S.
    Gotic, M.
    Mihaljevic, B.
    HAEMATOLOGICA, 2012, 97 : 614 - 614
12345